Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary result of a randomized phase 2 trial

Author:

Luo Xi1,Huang Xiaodong1,Liu Shaoyan2,Wang Xiaolei2,He Xiaohui1,Luo Dehong1,Luo Jingwei1,Xiao Jianping1,Wang Kai1,Qu Yuan1,Chen Xuesong1,Zhang Ye1,Wu Runye1,Wang Jingbo1,Zhang Jianghu1,Xu Guozhen1,Gao Li1,Yi Junlin1

Affiliation:

1. National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College

2. National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Abstract

Abstract Purpose Concurrent chemoradiotherapy (CCRT) was one of the standard treatment choices for locally advanced hypopharyngeal carcinoma. The aim of this study was to investigate whether IC followed by CCRT is superior to CCRT in locally advanced hypopharyngeal carcinoma. Methods and Materials: 142 patients were randomized to receive two cycles of docetaxal /cisplatin/5-fluorouracil (TPF) IC followed by CCRT or CCRT alone. The primary end point was overall survival (OS). Secondary end points included larynx-preservation rate, progression-free survival (PFS), distant metastasis-free survival (DMFS) and toxicities. Results 113 of 142 patients were finally analyzed. With a median follow-up of 45.6 months (IQR 26.8–57.8), the 3-year OS was 53.1% in the IC + CCRT compared with 54.8% in the CCRT (HR, 1.004; 95% CI, 0.573 to 1.761; P = 0.988). There were no statistically significant differences in PFS, DMFS and larynx-preservation rate between the two groups. Grade 3–4 hematological toxicity incidence was much higher in the IC + CCRT group than that in the CCRT group (54.7% vs 10%, P < 0.001). Conclusions Adding induction TPF to CCRT could not improve the survival and larynx-preservation rate in locally advanced hypopharyngeal cancer but in the cost of higher acute hematological toxicities.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3